In total, 135 companies take part in the 2018/19 programme compared with 30 companies in 2015. On average, participants generate annual revenues of over €10m, and employ 100 staff. They are also at increasingly mature stage of growth as two-thirds are venture capital-backed and they have each raised around €15m in capital.
Since its launch in 2015, TechShare has helped four French companies access capital markets: Osmozis, Balyo, Oxatis, and biopharmaceutical company Theranexus. Among the biotech companies in the 2018/19 training programme are Thermosome (Germany), SOM Biotech (Spain), Sirion Biotech (Germany), Silk Biomaterials (Italy), OncoDNA (Belgium), Novadiscovery (France), Numares Health (Germany), Minory Therapeutics (Spain), LNC Therapeutics (France), Histocell (Spain), Genenta Science (Italy), Gecko Biomedical (France), Enyo Pharma (France), Cardior (Germany), Algentech (France) and Abionic (Switzerland).
In the same category
EMA & FDA Apply a Similar Mindset When Providing Scientific Advice For Live Biotherapeutic...
Sep 13, 2021more +
Bordeaux : un traitement prometteur contre l’obésité développé à base d’une...
Jun 16, 2021more +
Le pari gagnant du microbiome
May 24, 2021more +